A Novel Subcutaneous Platelet GPIIb/IIIa Inhibitor in STEMI
C. Michael Gibson and Dean Kereiakes discuss the first human use of RUC-4, designed for STEMI point-of-care treatment.
Related Articles
Similar Safety, Efficacy With Leadless vs Transvenous Pacemakers at 2 Years in Medicare Population
The ongoing evolution of these devices position them as potentially good options for some patients, experts say.
Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF
The changes seen during peak exercise alone led to better RV-PA coupling, which may be the reason for the benefit.
Bioprosthetic Valve Durability: What Do We Know?
Phillipe Pibarot joins Changfu Wu and Larry Wood to talk about significant clinical endpoints and differences in durability among bioprosthetic valves.
AI Expected to Augment Workload, Not Put Cardiac Imagers Out of Work
AI and machine-learning algorithms will take on many tasks, but humans will have to contextualize the results, experts predict.
Improved Lipids With Gastric Bypass Linked to Surgery Itself, Not Weight Loss
Caloric intake and weight loss can’t explain the reduction in LDL and apoB, suggesting the RYGB surgery itself is plays a role.
Genetic Tests for Predicting Clopidogrel Response Gain Traction: AHA
Although clinical guidelines haven’t yet taken a firm stance, a new document says that routinely assessing CYP2C19 makes sense.
Aortic Wall Thrombus in TAVI Patients Portends Thromboembolic Events
AWT was tied to starkly higher risks, but with no proof of a causative link, more needs to be done before changing practice.
Advances in the Management of AR
Robert Bonow talks to Lauren Ranard about the future of treatments for aortic regurgitation, including new imaging tools and parameters that can improve outcomes and…
Evolut TAVI Shows Promise in Low-risk Bicuspid Patients at 3 Years
The best bicuspid strategy remains elusive without an RCT, but the data should reassure that TAVI isn’t necessarily “wrong.”
For Pragmatic RCTs, Patient-Reported ‘Hard’ Events Fall Short
For all hard endpoints, 90% of events were captured in claims data or EHR, with the minority stemming from patient reports.